Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 150

Similar articles for PubMed (Select 18533412)

1.

Revaccination of adults with spinal cord injury using the 23-valent pneumococcal polysaccharide vaccine.

Waites KB, Canupp KC, Chen YY, DeVivo MJ, Nahm MH.

J Spinal Cord Med. 2008;31(1):53-9.

2.

Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.

Musher DM, Manof SB, Liss C, McFetridge RD, Marchese RD, Bushnell B, Alvarez F, Painter C, Blum MD, Silber JL.

J Infect Dis. 2010 Feb 15;201(4):516-24. doi: 10.1086/649839.

3.

Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = years.

Manoff SB, Liss C, Caulfield MJ, Marchese RD, Silber J, Boslego J, Romero-Steiner S, Rajam G, Glass NE, Whitney CG, Carlone GM.

J Infect Dis. 2010 Feb 15;201(4):525-33. doi: 10.1086/651131.

4.

Pneumococcal polysaccharide revaccination: immunoglobulin g seroconversion, persistence, and safety in frail, chronically ill older subjects.

Lackner TE, G Hamilton R, J Hill J, Davey C, Guay DR.

J Am Geriatr Soc. 2003 Feb;51(2):240-5.

PMID:
12558722
5.

A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma.

Landgren O, Björkholm M, Konradsen HB, Söderqvist M, Nilsson B, Gustavsson A, Axdorph U, Kalin M, Grimfors G.

J Intern Med. 2004 Jun;255(6):664-73.

PMID:
15147530
6.

Immune responses of splenectomized trauma patients to the 23-valent pneumococcal polysaccharide vaccine at 1 versus 7 versus 14 days after splenectomy.

Shatz DV, Schinsky MF, Pais LB, Romero-Steiner S, Kirton OC, Carlone GM.

J Trauma. 1998 May;44(5):760-5; discussion 765-6.

PMID:
9603075
7.

Immunogenicity of pneumococcal vaccine in persons with spinal cord injury.

Waites KB, Canupp KC, Edwards K, Palmer P, Gray BM, DeVivo MJ.

Arch Phys Med Rehabil. 1998 Dec;79(12):1504-9.

PMID:
9862290
8.

Pneumococcal vaccination for patients with spinal cord injury.

Darouiche RO, Groover J, Rowland J, Musher DM.

Arch Phys Med Rehabil. 1993 Dec;74(12):1354-7.

PMID:
8259905
9.

Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination.

Mufson MA, Hughey DF, Turner CE, Schiffman G.

Vaccine. 1991 Jun;9(6):403-7.

PMID:
1887670
10.
11.

[Persistence of antibodies three years after vaccination with the 23-valent pneumococcal vaccine].

Campins Martí M, Casal Lombos J, Tarragó Asensio D, Rodrigo Anoro MJ, Allepuz Palau A, Callís Bracons L.

An Pediatr (Barc). 2003 Feb;58(2):184-7. Spanish.

12.

IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.

Soininen A, Nohynek H, Lucero M, Jousimies K, Ugpo J, Williams G, Käyhty H; ARIVAC Consortium.

Vaccine. 2009 May 5;27(20):2680-8. doi: 10.1016/j.vaccine.2009.02.059. Epub 2009 Feb 24.

PMID:
19428879
13.
14.

Randomised revaccination with pneumococcal polysaccharide or conjugate vaccine in asplenic children previously vaccinated with polysaccharide vaccine.

Smets F, Bourgois A, Vermylen C, Brichard B, Slacmuylders P, Leyman S, Sokal E.

Vaccine. 2007 Jul 20;25(29):5278-82. Epub 2007 Jun 4.

PMID:
17576024
15.

Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults.

Grabenstein JD, Manoff SB.

Vaccine. 2012 Jun 22;30(30):4435-44. doi: 10.1016/j.vaccine.2012.04.052. Epub 2012 Apr 26. Review.

PMID:
22542818
16.

Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in Brazilian elderly.

Simonsen V, Brandão AP, Brandileone MC, Yara TI, Di Fabio JL, Lopes MH, Jacob Filho W.

Braz J Med Biol Res. 2005 Feb;38(2):251-60. Epub 2005 Feb 15.

17.

Immune response to pneumococcal conjugate vaccination in asplenic individuals.

Stanford E, Print F, Falconer M, Lamden K, Ghebrehewet S, Phin N, Baxter D, Helbert M, McCann R, Andrews N, Balmer P, Borrow R, Kaczmarski E.

Hum Vaccin. 2009 Feb;5(2):85-91. Epub 2009 Feb 7.

18.

Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness.

Hammitt LL, Bulkow LR, Singleton RJ, Nuorti JP, Hummel KB, Miernyk KM, Zanis C, Whaley M, Romero-Steiner S, Butler JC, Rudolph K, Hennessy TW.

Vaccine. 2011 Mar 9;29(12):2287-95. doi: 10.1016/j.vaccine.2011.01.029. Epub 2011 Jan 19.

PMID:
21255685
19.

Type-specific antibodies to pneumococcal capsular polysaccharide acquired either naturally or after vaccination with Prevenar in children with underlying chronic or recurrent lung diseases.

Navarro D, Escribano A, Cebrián L, Gimeno C, García-Maset L, García-de-Lomas J; Spanish Pneumococcal Infection Study Network.

Clin Vaccine Immunol. 2006 Jun;13(6):665-70.

20.

Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.

Miernyk KM, Butler JC, Bulkow LR, Singleton RJ, Hennessy TW, Dentinger CM, Peters HV, Knutsen B, Hickel J, Parkinson AJ.

Clin Infect Dis. 2009 Jul 15;49(2):241-8. doi: 10.1086/599824.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk